Profile data is unavailable for this security.
About the company
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
- Revenue in USD (TTM)6.31m
- Net income in USD-425.87m
- Incorporated2004
- Employees143.00
- LocationPrecigen Inc20374 SENECA MEADOWS PARKWAYGERMANTOWN 20876United StatesUSA
- Phone+1 (301) 556-9900
- Websitehttps://precigen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharmaceutical Inc | 757.07m | 58.44m | 1.45bn | 357.00 | 28.56 | 5.27 | 5.09 | 1.91 | 1.60 | 1.60 | 19.94 | 8.70 | 0.467 | 8.51 | 3.27 | 2,120,636.00 | 3.60 | 4.11 | 5.02 | 6.64 | 57.22 | 55.50 | 7.72 | 8.48 | 1.27 | 2.23 | 0.7462 | 0.00 | 11.41 | 16.31 | 43.68 | -- | -23.82 | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.62bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 379.59m | -29.23m | 1.63bn | 493.00 | -- | -- | -- | 4.30 | -0.5866 | -0.5866 | 7.49 | -- | 0.3471 | 0.5336 | 5.44 | 769,959.40 | -2.67 | -17.90 | -3.34 | -23.26 | 99.29 | -- | -7.70 | -53.74 | 5.97 | -- | 0.4975 | -- | 24.37 | 56.77 | 7.60 | -- | -1.06 | -- |
| Innoviva Inc | 388.52m | 127.34m | 1.70bn | 127.00 | 17.59 | 1.68 | 10.14 | 4.37 | 1.29 | 1.29 | 4.57 | 13.51 | 0.292 | 1.98 | 4.21 | 3,059,221.00 | 9.57 | 20.06 | 10.66 | 22.10 | 81.50 | -- | 32.78 | 62.81 | 13.33 | 18.15 | 0.2031 | -- | 15.54 | 6.57 | -86.98 | -31.69 | 223.78 | -- |
| ANI Pharmaceuticals Inc | 826.88m | 34.14m | 1.74bn | 897.00 | 47.44 | 3.44 | 13.33 | 2.10 | 1.63 | 1.63 | 40.89 | 22.51 | 0.6135 | 2.18 | 3.68 | 921,828.30 | 3.01 | -2.99 | 3.63 | -3.49 | 61.14 | 58.84 | 4.91 | -6.12 | 2.04 | 3.83 | 0.5508 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| Precigen Inc | 6.31m | -425.87m | 1.74bn | 143.00 | -- | 41.66 | -- | 276.49 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Harrow Inc | 250.04m | -4.99m | 1.77bn | 382.00 | -- | 37.57 | 129.10 | 7.06 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
| Vericel Corp | 258.72m | 13.08m | 1.82bn | 357.00 | 192.09 | 5.65 | 78.45 | 7.03 | 0.1872 | 0.1872 | 4.86 | 6.37 | 0.6133 | 4.00 | 4.75 | 724,697.50 | 3.10 | -1.03 | 3.46 | -1.18 | 73.81 | 69.10 | 5.06 | -1.61 | 4.47 | -- | 0.002 | -- | 20.10 | 15.02 | 425.64 | -- | 89.53 | -- |
| Sarepta Therapeutics Inc | 2.41bn | -271.51m | 1.86bn | 1.37k | -- | 1.41 | -- | 0.7723 | -3.19 | -3.19 | 22.09 | 12.60 | 0.6806 | 0.6977 | 5.81 | 1,759,268.00 | -7.66 | -12.82 | -9.92 | -15.47 | 76.25 | 85.53 | -11.25 | -37.16 | 1.79 | -- | 0.4395 | -- | 52.97 | 37.94 | 143.89 | -- | 18.57 | -- |
| Aurinia Pharmaceuticals Inc | 265.81m | 77.84m | 1.88bn | 300.00 | 25.37 | 5.13 | 19.28 | 7.06 | 0.561 | 0.561 | 1.88 | 2.77 | 0.4937 | 0.7046 | 7.91 | -- | 14.46 | -18.84 | 16.88 | -20.97 | 88.93 | -- | 29.28 | -72.47 | 5.17 | -- | 0.1645 | -- | 33.97 | 274.78 | 107.37 | -- | 22.71 | -- |
| Organon & Co | 6.30bn | 501.00m | 1.92bn | 10.00k | 3.84 | 2.12 | 2.28 | 0.3049 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Ocular Therapeutix Inc | 51.95m | -265.94m | 1.93bn | 325.00 | -- | 2.93 | -- | 37.21 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Ultragenyx Pharmaceutical Inc | 672.72m | -575.44m | 1.98bn | 1.29k | -- | -- | -- | 2.94 | -5.84 | -5.84 | 6.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 83.85 | 88.44 | -85.54 | -122.25 | -- | -12.60 | -- | -- | 20.13 | 19.95 | -1.02 | -- | -- | -- |
| Perrigo Company PLC | 4.28bn | -29.20m | 2.00bn | 8.38k | -- | 0.45 | 6.61 | 0.4673 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.07bn | 246.00 | 11.34 | 2.48 | 9.90 | 2.51 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.12bn | 2.48k | 23.17 | 6.37 | 14.83 | 1.45 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
Data as of Feb 17 2026. Currency figures normalised to Precigen Inc's reporting currency: US Dollar USD
32.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Patient Capital Management LLC (Invt Mgmt)as of 31 Dec 2025 | 18.67m | 6.26% |
| Point72 Asset Management LPas of 22 Jan 2026 | 18.38m | 6.16% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 13.25m | 4.44% |
| Tang Capital Management LLCas of 30 Sep 2025 | 12.40m | 4.16% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 10.82m | 3.63% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 9.01m | 3.02% |
| Geode Capital Management LLCas of 31 Dec 2025 | 4.46m | 1.50% |
| Diametric Capital LPas of 31 Dec 2025 | 3.85m | 1.29% |
| Iridian Asset Management LLCas of 31 Dec 2025 | 3.60m | 1.21% |
| Occam Crest Management LPas of 31 Dec 2025 | 3.50m | 1.17% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
